DexCom Inc. (DXCM): Price and Financial Metrics


DexCom Inc. (DXCM): $118.11

0.08 (+0.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DXCM POWR Grades

  • DXCM scores best on the Growth dimension, with a Growth rank ahead of 93.75% of US stocks.
  • The strongest trend for DXCM is in Stability, which has been heading up over the past 179 days.
  • DXCM's current lowest rank is in the Momentum metric (where it is better than 1.14% of US stocks).

DXCM Stock Summary

  • DXCM has a higher market value than 94.64% of US stocks; more precisely, its current market capitalization is $43,481,077,131.
  • DXCM's current price/earnings ratio is 189.05, which is higher than 97.72% of US stocks with positive earnings.
  • The volatility of DEXCOM INC's share price is greater than that of 97.99% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to DXCM, based on their financial statements, market capitalization, and price volatility, are FSLR, NBIX, CALX, ESMT, and MELI.
  • Visit DXCM's SEC page to see the company's official filings. To visit the company's web site, go to www.dexcom.com.

DXCM Valuation Summary

  • In comparison to the median Healthcare stock, DXCM's price/sales ratio is 222.92% higher, now standing at 15.5.
  • Over the past 214 months, DXCM's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for DXCM.

Stock Date P/S P/B P/E EV/EBIT
DXCM 2022-11-25 15.5 23.7 188.1 159.1
DXCM 2022-11-23 15.6 23.9 189.6 160.4
DXCM 2022-11-22 15.4 23.5 186.4 157.8
DXCM 2022-11-21 15.6 23.9 189.2 160.0
DXCM 2022-11-18 15.7 24.1 191.0 161.5
DXCM 2022-11-17 15.6 23.8 189.2 160.0

DXCM Growth Metrics

    Its year over year revenue growth rate is now at 26.93%.
  • The 5 year net income to common stockholders growth rate now stands at 325.46%.
  • Its 3 year net cashflow from operations growth rate is now at 238%.
Over the past 52 months, DXCM's revenue has gone up $1,960,300,000.

The table below shows DXCM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2,792.8 642.8 230
2022-06-30 2,673.4 596.9 199.7
2022-03-31 2,572.3 485.7 211.7
2021-12-31 2,448.5 442.5 154.7
2021-09-30 2,319.2 508.7 529.3
2021-06-30 2,169.9 409 530.6

DXCM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DXCM has a Quality Grade of B, ranking ahead of 87.89% of graded US stocks.
  • DXCM's asset turnover comes in at 0.517 -- ranking 89th of 186 Medical Equipment stocks.
  • VRAY, ZYXI, and SRTS are the stocks whose asset turnover ratios are most correlated with DXCM.

The table below shows DXCM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.517 0.693 0.081
2021-06-30 0.510 0.692 0.077
2021-03-31 0.506 0.675 0.070
2020-12-31 0.547 0.664 0.077
2020-09-30 0.597 0.654 0.089
2020-06-30 0.651 0.639 0.090

DXCM Price Target

For more insight on analysts targets of DXCM, see our DXCM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $530.60 Average Broker Recommendation 1.36 (Strong Buy)

DXCM Stock Price Chart Interactive Chart >

Price chart for DXCM

DXCM Price/Volume Stats

Current price $118.11 52-week high $144.96
Prev. close $118.03 52-week low $66.89
Day low $115.31 Volume 1,883,653
Day high $118.51 Avg. volume 3,200,380
50-day MA $104.28 Dividend yield N/A
200-day MA $95.32 Market Cap 45.62B

DexCom Inc. (DXCM) Company Bio


Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. (Source:Wikipedia)


DXCM Latest News Stream


Event/Time News Detail
Loading, please wait...

DXCM Latest Social Stream


Loading social stream, please wait...

View Full DXCM Social Stream

Latest DXCM News From Around the Web

Below are the latest news stories about DEXCOM INC that investors may wish to consider to help them evaluate DXCM as an investment opportunity.

Is This Stock-Split Stock a Buy For 2023?

Over the past 10 months, several high-profile stock splits helped animate an already lively stock market. One of them was that of the medical device expert DexCom (NASDAQ: DXCM), which completed a 4-for-1 stock split in June. Of course, stock splits don't fundamentally change the prospects of the company, and DexCom's did little to jolt its stock performance in 2022.

Yahoo | November 26, 2022

Dexcom Leads 5 Stocks Near Buy Points

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.

Yahoo | November 26, 2022

Dow Jones Futures Rise: 5 Stocks Near Buy Points In Market Rally; Tesla FSD Beta Expands Widely

The S&P 500 still faces its 200-day line with key economic data looming. Tesla FSD Beta gets a wide release after TSLA stock jumped from bear market lows.

Yahoo | November 25, 2022

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO, November 22, 2022--DexCom, Inc. (NASDAQ:DXCM) today announced that Matt Dolan, Executive Vice President, Strategy, Corporate Development and Dexcom Labs, will present an update on the company at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022 at 8:30am (EST).

Yahoo | November 22, 2022

3 Stocks to Buy for Long-Term Growth Upside

Investors might want to consider buying stocks after the strong first half of the fourth quarter. Today, we explore three stocks that are set to expand within three crucial growth industries.

Yahoo | November 18, 2022

Read More 'DXCM' Stories Here

DXCM Price Returns

1-mo 1.86%
3-mo 44.04%
6-mo 61.36%
1-year -15.67%
3-year 106.61%
5-year 714.27%
YTD -12.01%
2021 45.23%
2020 69.02%
2019 82.59%
2018 108.75%
2017 -3.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.657 seconds.